BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $836,600.00 in Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating) CEO Jean Jacques Bienaime sold 10,000 shares of the business’s stock in a transaction dated Thursday, April 14th. The shares were sold at an average price of $83.66, for a total value of $836,600.00. Following the sale, the chief executive officer now owns 334,983 shares of the company’s stock, valued at $28,024,677.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Thursday, March 10th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $77.57, for a total value of $1,163,550.00.

Shares of NASDAQ BMRN traded down $1.77 during trading hours on Monday, hitting $81.18. 992,026 shares of the company traded hands, compared to its average volume of 1,308,297. The stock has a market capitalization of $14.94 billion, a price-to-earnings ratio of -225.50, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49. The company has a current ratio of 4.21, a quick ratio of 2.77 and a debt-to-equity ratio of 0.25. The company’s 50 day moving average price is $81.66 and its 200 day moving average price is $83.20. BioMarin Pharmaceutical Inc. has a 12 month low of $71.59 and a 12 month high of $94.20.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) last announced its quarterly earnings data on Wednesday, February 23rd. The biotechnology company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The company had revenue of $449.81 million for the quarter, compared to the consensus estimate of $442.38 million. BioMarin Pharmaceutical had a positive return on equity of 1.32% and a negative net margin of 3.47%. BioMarin Pharmaceutical’s quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.05) EPS. Equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 0.89 EPS for the current year.

BMRN has been the subject of a number of recent research reports. Piper Sandler boosted their price target on BioMarin Pharmaceutical from $121.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, February 24th. Morgan Stanley boosted their price target on BioMarin Pharmaceutical from $90.00 to $96.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 12th. StockNews.com initiated coverage on BioMarin Pharmaceutical in a research note on Thursday, March 31st. They set a “hold” rating for the company. Truist Financial boosted their price target on BioMarin Pharmaceutical from $125.00 to $135.00 in a research note on Monday, January 10th. Finally, Wedbush restated an “outperform” rating and set a $155.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 24th. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $112.14.

A number of institutional investors have recently made changes to their positions in BMRN. Ancora Advisors LLC grew its position in BioMarin Pharmaceutical by 466.7% in the 3rd quarter. Ancora Advisors LLC now owns 425 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 350 shares during the last quarter. Spire Wealth Management lifted its holdings in shares of BioMarin Pharmaceutical by 59.7% in the 4th quarter. Spire Wealth Management now owns 377 shares of the biotechnology company’s stock worth $33,000 after buying an additional 141 shares during the period. Liberty Wealth Management LLC lifted its holdings in shares of BioMarin Pharmaceutical by 181.7% in the 3rd quarter. Liberty Wealth Management LLC now owns 431 shares of the biotechnology company’s stock worth $34,000 after buying an additional 278 shares during the period. Close Asset Management Ltd lifted its holdings in shares of BioMarin Pharmaceutical by 32,400.0% in the 3rd quarter. Close Asset Management Ltd now owns 650 shares of the biotechnology company’s stock worth $50,000 after buying an additional 648 shares during the period. Finally, Desjardins Global Asset Management Inc. purchased a new stake in shares of BioMarin Pharmaceutical during the 4th quarter worth $53,000. 91.71% of the stock is currently owned by institutional investors.

About BioMarin Pharmaceutical (Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Articles

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.